A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
• Males and females at 18-75 years of age, inclusive, at the Screening Visit.
• Have a clinical diagnosis of pancreatic cancer.
• An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
• Expected survival time of≥6 months.
• No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.
Locations
Other Locations
China
Guangdong Provincial People's Hospital
RECRUITING
Guangzhou
Contact Information
Primary
Chen RF Prof.
chenrf63@163.com
020-83525210
Time Frame
Start Date: 2025-03-17
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 18
Treatments
Experimental: VRT106 combination with chemotherapy
VRT106 combination with chemotherapy
Related Therapeutic Areas
Sponsors
Leads: Guangdong Provincial People's Hospital
Collaborators: Guangzhou Virotech Pharmaceutical Co., Ltd.